DK1337247T3 - Anvendelse af Gaboxadol til behandling af præmenstruel forstyrrelse, födselsdepression eller postmenopausalt relateret disforisk forstyrrelse - Google Patents

Anvendelse af Gaboxadol til behandling af præmenstruel forstyrrelse, födselsdepression eller postmenopausalt relateret disforisk forstyrrelse

Info

Publication number
DK1337247T3
DK1337247T3 DK01996378T DK01996378T DK1337247T3 DK 1337247 T3 DK1337247 T3 DK 1337247T3 DK 01996378 T DK01996378 T DK 01996378T DK 01996378 T DK01996378 T DK 01996378T DK 1337247 T3 DK1337247 T3 DK 1337247T3
Authority
DK
Denmark
Prior art keywords
disorder
gaboxadol
birth
depression
postmenopausal
Prior art date
Application number
DK01996378T
Other languages
Danish (da)
English (en)
Inventor
Bjarke Ebert
Andersen Peter Hongaard
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8159857&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1337247(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Application granted granted Critical
Publication of DK1337247T3 publication Critical patent/DK1337247T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
DK01996378T 2000-11-20 2001-11-20 Anvendelse af Gaboxadol til behandling af præmenstruel forstyrrelse, födselsdepression eller postmenopausalt relateret disforisk forstyrrelse DK1337247T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200001743 2000-11-20

Publications (1)

Publication Number Publication Date
DK1337247T3 true DK1337247T3 (da) 2006-12-04

Family

ID=8159857

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01996378T DK1337247T3 (da) 2000-11-20 2001-11-20 Anvendelse af Gaboxadol til behandling af præmenstruel forstyrrelse, födselsdepression eller postmenopausalt relateret disforisk forstyrrelse

Country Status (33)

Country Link
US (2) US20040024038A1 (cs)
EP (1) EP1337247B1 (cs)
JP (1) JP4152186B2 (cs)
KR (1) KR100865651B1 (cs)
CN (1) CN1318027C (cs)
AR (1) AR031473A1 (cs)
AT (1) ATE336242T1 (cs)
AU (2) AU2351402A (cs)
BG (1) BG107909A (cs)
BR (1) BR0115668A (cs)
CA (1) CA2429220C (cs)
CY (1) CY1106209T1 (cs)
CZ (1) CZ20031383A3 (cs)
DE (1) DE60122368T2 (cs)
DK (1) DK1337247T3 (cs)
EA (1) EA007287B1 (cs)
ES (1) ES2266308T3 (cs)
HR (1) HRP20030404A2 (cs)
HU (1) HUP0400505A3 (cs)
IL (1) IL155587A0 (cs)
IS (1) IS2427B (cs)
ME (1) MEP6408A (cs)
MX (1) MXPA03004349A (cs)
NO (1) NO20032271D0 (cs)
NZ (1) NZ525520A (cs)
PL (1) PL361051A1 (cs)
PT (1) PT1337247E (cs)
SI (1) SI1337247T1 (cs)
SK (1) SK7682003A3 (cs)
UA (1) UA77403C2 (cs)
WO (1) WO2002040009A1 (cs)
YU (1) YU39003A (cs)
ZA (1) ZA200303289B (cs)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
WO2003045411A2 (de) * 2001-11-26 2003-06-05 Finzelberg Gmbh & Co. Kg Ingwer-extraktzubereitung
SI1641456T1 (sl) * 2003-06-25 2010-06-30 Lundbeck & Co As H Gaboksadol za zdravljenje depresije in drugih afektivnih motenj
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
AU2004324938A1 (en) * 2004-06-29 2006-05-26 H. Lundbeck A/S Treatment of neuropathic pain, fibromyalgia or rheumatoid arthritis
WO2006012563A2 (en) * 2004-07-23 2006-02-02 The Regents Of The University Of California Method for the treatment and diagnosis of certain psychiatric disorders related to the menstrual cycle
GB0417558D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
US8022084B2 (en) 2005-01-28 2011-09-20 H. Lundbeck A/S Polymorphic forms of a GABAA agonist
US20070122507A1 (en) * 2005-05-26 2007-05-31 Palu Afa K Histone deacetylase and tumor necrosis factor converting enzyme inhibition
US9209995B2 (en) * 2006-12-29 2015-12-08 Prodea Systems, Inc. Presence status notification from digital endpoint devices through a multi-services gateway device at the user premises
US20080280983A1 (en) * 2007-05-09 2008-11-13 Cenerx Biopharma Methods of treating rett syndrome
CN101585862B (zh) * 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
WO2012173634A1 (en) * 2011-06-16 2012-12-20 Solace Lifesciences, Inc. Systems and methods for balancing and maintaining the health of the human autonomic nervous system
RU2496496C1 (ru) * 2012-10-04 2013-10-27 Исаак Григорьевич Гитлин Фармацевтическая композиция, обладающая гамк-ергической активностью
PE20230735A1 (es) 2015-07-17 2023-05-03 Ovid Therapeutics Inc Metodos de tratamiento de trastornos del desarrollo con gaboxadol
EP3586845A1 (en) * 2016-08-11 2020-01-01 Ovid Therapeutics, Inc. Compositions for treatment of essential tremor
US20180338959A1 (en) * 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
KR102049526B1 (ko) * 2018-06-05 2019-11-27 충남대학교산학협력단 Gaba를 유효성분으로 하는 항결핵 약학 조성물
KR102049522B1 (ko) * 2018-06-05 2019-11-27 충남대학교산학협력단 Gaba를 유효성분으로 하는 살모넬라 감염질환의 예방 및 치료용 조성물
CN112930182A (zh) 2018-09-20 2021-06-08 奥维德医疗公司 加波沙朵用于治疗图雷特综合征、抽搐和口吃的用途
EP3883566A4 (en) 2018-11-21 2022-09-07 Certego Therapeutics Inc. GABOXADOL FOR REDUCE RISK OF SUICIDE AND RAPID RELIEF OF DEPRESSION
CN113423399A (zh) 2018-12-17 2021-09-21 奥维德医疗公司 加波沙朵用于治疗非24小时睡眠-觉醒障碍的用途
WO2020212952A1 (en) 2019-04-17 2020-10-22 Compass Pathfinder Limited Treatment of depression and other various disorders with psilocybin
CN114786669A (zh) 2019-12-18 2022-07-22 奥维德医疗公司 用于1p36缺失综合征的治疗性治疗的加波沙朵
CN116267014A (zh) 2020-05-20 2023-06-20 Certego治疗公司 环状氘化加波沙朵及其用于治疗精神障碍的用途
CN114404437A (zh) * 2022-03-15 2022-04-29 山东中医药大学 没食子酰芍药苷在制备gabaa受体抑制剂中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4362731A (en) * 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US5120723A (en) * 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
WO1993005786A1 (en) * 1991-09-13 1993-04-01 Cocensys, Inc. Novel gabaa receptor with steroid binding sites
US5206415A (en) * 1991-12-20 1993-04-27 Washington University Tricyclic steroid analogs
CZ300694A3 (en) * 1993-12-02 1996-05-15 Akzo Nobel Nv Substituted 2beta-morpholinandrostane derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical compositions containing thereof
ES2155543T3 (es) * 1994-11-23 2001-05-16 Cocensys Inc Serie de androstano y pregnano para modulacion alosterica del receptor de gaba.
US5776959A (en) * 1995-06-05 1998-07-07 Washington University Anticonvulsant and anxiolytic lactam and thiolactam derivatives
PT837874E (pt) * 1995-06-06 2005-03-31 Euro Celtique Sa Esteroides neuroactivos da serie androstano e pregnano
IT1290003B1 (it) * 1997-03-03 1998-10-19 Angelini Ricerche Spa Uso di pivagabina per preparare composizioni farmaceutiche
GB9801208D0 (en) * 1998-01-21 1998-03-18 Merck Sharp & Dohme Therapeutic agents
US6451854B1 (en) * 1998-07-22 2002-09-17 Akzo Nobel N.V. α-amino acid phenyl ester derivatives
CN1407967A (zh) * 1999-12-08 2003-04-02 沃尼尔·朗伯公司 立体选择性地合成环状氨基酸的方法

Also Published As

Publication number Publication date
CZ20031383A3 (cs) 2003-08-13
NO20032271L (no) 2003-05-20
IL155587A0 (en) 2003-11-23
MEP6408A (xx) 2010-02-10
ES2266308T3 (es) 2007-03-01
AU2351402A (en) 2002-05-27
ZA200303289B (en) 2005-07-27
UA77403C2 (en) 2006-12-15
ATE336242T1 (de) 2006-09-15
KR100865651B1 (ko) 2008-10-29
US20090143435A1 (en) 2009-06-04
JP4152186B2 (ja) 2008-09-17
KR20030065517A (ko) 2003-08-06
HUP0400505A3 (en) 2008-08-28
HK1075010A1 (en) 2005-12-02
AR031473A1 (es) 2003-09-24
DE60122368T2 (de) 2007-08-09
PL361051A1 (en) 2004-09-20
JP2004513921A (ja) 2004-05-13
PT1337247E (pt) 2006-11-30
CA2429220A1 (en) 2002-05-23
IS6803A (is) 2003-04-30
CN1318027C (zh) 2007-05-30
EA200300594A1 (ru) 2003-10-30
SK7682003A3 (en) 2003-10-07
BR0115668A (pt) 2003-09-02
AU2002223514B2 (en) 2006-11-30
HUP0400505A2 (hu) 2004-07-28
CN1592616A (zh) 2005-03-09
DE60122368D1 (de) 2006-09-28
EA007287B1 (ru) 2006-08-25
WO2002040009A1 (en) 2002-05-23
NZ525520A (en) 2005-04-29
YU39003A (sh) 2006-05-25
MXPA03004349A (es) 2003-08-19
IS2427B (is) 2008-10-15
EP1337247B1 (en) 2006-08-16
BG107909A (bg) 2004-08-31
CA2429220C (en) 2009-09-15
NO20032271D0 (no) 2003-05-20
CY1106209T1 (el) 2011-06-08
HRP20030404A2 (en) 2005-04-30
US20040024038A1 (en) 2004-02-05
EP1337247A1 (en) 2003-08-27
SI1337247T1 (sl) 2006-12-31

Similar Documents

Publication Publication Date Title
DK1337247T3 (da) Anvendelse af Gaboxadol til behandling af præmenstruel forstyrrelse, födselsdepression eller postmenopausalt relateret disforisk forstyrrelse
CY2013048I1 (el) Παραλλαγη τροποποιημενου ιου vaccinia ankara
DK1259218T3 (da) Kosmetisk sammensætning til behandling af aldrende og/eller stresset hud
ATE407153T1 (de) Katalysatorbestandteile zur olefinpolymerisation
NO2016006I1 (no) Prodroger av fosfonatnukleotidanaloger,preparat derav og dets anvendelse til terapeutisk og profylaktisk behandling av virusinfeksjoner
ATE354360T1 (de) Amidoacetonitrile zur bekämpfung von endoparasiten
ATE473944T1 (de) Mittel zur wasserbehandlung
NO20035325D0 (no) Hudpermeabelt selektiv cyklooksygenase-2-inhibitorpreparat
EP1318798A4 (en) PROPOFOL-BASED WATER-SOLUBLE DRUGS TO TREAT MIGRAINE
CL2005002823A1 (es) Anticuerpos anti-virus respiratorio sincitial, antigenos y usos de los mismos
NO2012018I1 (no) Canakinumab eller direkte ekvivalenter derav
DE60128186D1 (de) Abgasreinigungskatalysator
DE60122243D1 (de) Abgasreinigungskatalysator
DE50103557D1 (de) Assistenzsystem zur auswahl von strecken
DE60138513D1 (de) Abgasreinigungskatalysator
BR0205514B1 (pt) processos de tratamento de cabelo
DK1309581T3 (da) Fremgangsmåde til fremstilling af citalopram
DE60138984D1 (de) Abgasreinigungskatalysator
DK1345939T3 (da) Fremgangsmåde til fremstilling af sulfonamidsubstituerede imidazotriazinoner
DE60142051D1 (de) Herstellung von perfluorolefinen
IS7035A (is) Örhylki til að halda andardrætti ferskum
DK1250148T3 (da) Anvendelse af FSH til behandling af infertilitet
DK1268482T3 (da) Pyranoindoler til behandling af glaukom
DE50108607D1 (de) Verfahren zur Herstellung von 4-Aminodiphenylamin
DK1351697T3 (da) Lægemiddel til fremme af regenerationen af væv